Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 8, 2012American Journal of HematologyOpen Access

Cancer and coagulation

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with cancer at risk for or experiencing thromboembolism

Design

Review

Authors

AKAlok A. KhoranaCardio-Oncology

Discussion

Loading...

Member takes

Implication

Supports heparin/LMWH thromboprophylaxis in high-risk cancer patients; leaves open optimal regimens for prospective validation.

Structured PICO

P
Population
Patients with cancer at risk for or experiencing thromboembolism
I
Intervention
Thromboprophylaxis with unfractionated heparin or low-molecular-weight heparins (LMWHs) and treatment with LMWH

This review highlights the importance of risk assessment and the use of unfractionated heparin or LMWH for the prophylaxis and treatment of cancer-associated thrombosis.

Cite This Study

Alok A. Khorana (2012) studied this question.

synapsesocial.com/papers/6a7f6ab1ea270e40cde9054fhttps://doi.org/10.1002/ajh.23143

Topics

Anticoagulation in AF
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer2007 · 397 citations
  2. 2Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients2008 · 552 citations
  3. 3Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients2007 · 797 citations
  4. 4Impact of clinical trial design and execution-related factors on incidence of thromboembolic events in cancer patients: a systematic review and meta-analysis2008 · 24 citations
  5. 5Venous Thromboembolic Disease2008 · 227 citations